NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

393.20 -1.30 (-0.33%)

35.12% Gain from 52W Low

704.4K NSE+BSE Volume

NSE 02 Dec, 2025 10:10 AM (IST)

52,569.4

Market Cap

Market Leader

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

31 Jul 2019

393.20

-0.33%

Biocon (BIOS) reported robust revenue growth of ~30% YoY at Rs1,465Cr (vs. estimate of Rs1,548Cr), aided by strong growth in biologics (up 96% YoY) and small molecule (up 20% YoY). Branded formulation (down 9% YoY) and Research service business (up 4% YoY) dragged the growth in Q1.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

26 Jul 2019

393.20

-0.33%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

Revenues grew 30.4% YoY to | 1465.9 crore (I-direct estimate: | 1573.3 crore) mainly due to 96.0% YoY growth in biologics to | 490 crore (I-direct estimate: | 462.5 crore). EBITDA margins improved 868 bps YoY to 29.8% (I-direct estimate: 26.4%) mainly due to strong gross margin performance (71.0% vs. 61.4% in Q1FY19). EBITDA grew 83.9% YoY to | 437.5 crore against I-direct estimate of | 415.6 crore. Adjusted net profit grew 72.2% to...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

12 Jun 2019

393.20

-0.33%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

Biocon has turned ex-bonus from June 12, 2019 pursuant to the announcement in the board meeting held on April 25, 2019. The board has recommended the issue of bonus shares in proportion of one bonus share (face value of | 5 each) for every equity share held. Consequently, the share price has changed to | 263 /share. We remain positive on the stock on the back of strong prospects in both biologics and services (Syngene) segments. We believe the correction in the stock is overdone and the stock offers a compelling bet at the current level. We maintain our BUY...

Axis Direct decreased Buy price target of Biocon Ltd. to 440.0 on 01 Dec, 2025.

Biocon Ltd.

06 May 2019

393.20

-0.33%

Company Update:Biocon

Buy: Biocon Ltd.

Axis Direct

Biocon (BIOS) staged a strong performance in Q4, helped by robust growth in biologics business (up 87% YoY) and research services (up 30% YoY). BIOS reported stellar revenue growth of ~31% YoY at Rs1,529cr. Branded formulation segment witnessed softness in Q4

Axis Direct decreased Buy price target of Biocon Ltd. to 440.0 on 01 Dec, 2025.

Biocon Ltd.

26 Apr 2019

393.20

-0.33%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

Well poised to capture global biosimilars opportunity The biologics segment (28% of FY19 in total revenues) includes biosimilars, encompassing Rh-insulin, insulin analogs, monoclonal antibodies & recombinant proteins. The company has invested heavily in this space in the last two to three years. The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and emerging markets. We...

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Biocon Ltd.

25 Jan 2019

393.20

-0.33%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Biocon's Q3FY19 numbers were a comprehensive beat vis--vis Idirect estimates on all fronts. Revenues grew 45.6% YoY to | 1540.8 crore (I-direct estimate: | 1382.4 crore) mainly due to 136.6% YoY growth in biologics to | 449 crore (I-direct estimate: | 379.6 crore) EBITDA margins improved 375 bps YoY to 24.7% (I-direct estimate: 26.2%) mainly due to improvement in product mix. EBITDA grew 71.7% YoY to | 380.7 crore against I-direct estimates of | 362.1 crore Adjusted net profit grew 131.6% to | 212.9 crore (I-direct estimate:...

Axis Direct decreased Buy price target of Biocon Ltd. to 440.0 on 01 Dec, 2025.

Biocon Ltd.

25 Jan 2019

393.20

-0.33%

Strong earnings beat on solid traction in biologics

Neutral: Biocon Ltd.

Motilal Oswal

25 January 2019 BIOS reported strong revenues, up ~46% YoY to INR15.1b (est. INR14.1b), led by strong growth in Biologics (28% of sales) and Research Services business (30% of sales). Superior product mix led to ~610bp YoY rise in gross margin (GM). EBITDA margin expanded ~560bp YoY (+80bp QoQ) to 26.5% on back of higher gross margin and lower employee cost, down ~280bp (as % of sales). This impact was partially off-set by higher other expense, which was up ~330bp (as % of sales). Absolute EBITDA increased by ~85% YoY (+20% QoQ) to INR4.1b on revenue growth and margin expansion. EBIT margin for the Biologics segment stood at ~30% v/s (-3%) YoY and 25% QoQ. PAT more than doubled to INR2.2b, growing ~136% YoY on back of strong revenue growth, margin expansion, and lower tax rate at 16.7% v/s 25.2% in 3QFY18.

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Biocon Ltd.

09 Nov 2018

393.20

-0.33%

Model Trading Portfolio | Buy Biocon Ltd

Buy: Biocon Ltd.

Edelweiss

Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

26 Oct 2018

393.20

-0.33%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Strong Q2 numbers were on the back of 136% YoY growth in Biologics segment led by commercial launch of biosimilar...

Axis Direct decreased Buy price target of Biocon Ltd. to 440.0 on 01 Dec, 2025.

Biocon Ltd.

22 Oct 2018

393.20

-0.33%

Positive Committee opinion

Neutral: Biocon Ltd.

Motilal Oswal

22 October 2018 received a positive opinion from CHMP for its Herceptin biosimilar for the EU market. BIOS/Mylan also have in place the EU good manufacturing practices (GMP) certification for their drug product and drug substance facilities. Biocon/Mylan would be the fifth team to receive a positive opinion for Herceptin for the EU market. Amgen received positive opinion from CHMP in Mar-18 and is in process to get approval EU commission. Though the market size is considerable, there is settlement in place between Mylan and Roche for launching the same in EU market. The inspection history at BIOS facilities (both drug substance as well as drug product) indicates successful compliance in place and would not be a hurdle for approval of any product. Recently, BIOS successfully completed the USFDA inspection (periodic GMP inspection) at its drug substance facility at Bengaluru with zero 483s.

Biocon Ltd. is trading above all available SMAs

Is Biocon Ltd. worth buying?

733 Votes:

Buy 74.9%

Sell 16.37%

Hold 8.73%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf